10th Midwest C. elegans Meeting in Grand Rapids, MI at the Van Andel institute hosted by Nick Burton & Shreesh Raj Sammi. Keynote speaker Eric L. Greer, Associate Professor, Genetics Read more about 10th Midwest C. elegans Meeting – Conference date[…]
Meeting details and important dates
Meeting details and important dates
Meeting details and important dates
Meeting details and important dates
TAGC, or The Allied Genetics Conference, is GSA’s flagship conference that brings together scientists from multiple international biological research communities to share cutting-edge science, foster new collaborations, and strengthen existing Read more about TAGC 2024 – Conference dates[…]
Dr. Sudip Mondal has a Ph.D. in Physics and several years of postdoctoral research experience in neuroscience and microfluidics-based screening tools. He has developed several technologies that have translated to the market. One of his recent works at The University of Texas at Austin involved a high-throughput screening platform with C. elegans model systems, which is commercialized by vivoVerse. As a Director of Science, Sudip is responsible for developing new technologies and innovative assays to increase the vivoVerse product & service portfolio.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC, now vivoVerse. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at vivoVerse, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of vivoVerse (formerly Newormics)